Seven Eight Capital’s Fulgent Genetics FLGT Stock Holding History

Seven Eight Capital’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21,624	Closed	-$1.13M	–	624
2021 Q1	$1.13M	Hold	21,624	–	–	0.26%	142
2020 Q4	$1.13M	Buy	+21,624	New	+$904K	0.26%	144

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Seven Eight Capital's FLGT Position: Q2 2021 in Review

Seven Eight Capital sold out of Fulgent Genetics (FLGT) in Q2 2021, closing a stake of 21,624 shares — an estimated $1.13M sold.

Seven Eight Capital first reported a position in FLGT in Q4 2020 and held it in 2 quarters. The position peaked at $1.13M in Q1 2021. 254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

Seven Eight Capital reported no remaining Fulgent Genetics position as of Q2 2021 after selling out during the quarter.
Seven Eight Capital sold 21,624 Fulgent Genetics shares in Q2 2021, an estimated $1.13M.
Seven Eight Capital first reported a position in Fulgent Genetics in Q4 2020 and held it in 2 quarters.
Seven Eight Capital's Fulgent Genetics position peaked at $1.13M in Q1 2021.
254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on Seven Eight Capital's 13F filing for Q2 2021, filed 13 Aug 2021.